Rocket Pharmaceuticals Shares Slide Despite FDA Nod for Kresladi Gene Therapy

Key Facts

Rocket Pharmaceuticals (RCKT) shares experienced a decline despite receiving accelerated approval from the U.S. Food and Drug Administration (FDA) for its gene therapy, Kresladi. The therapy is designed to treat severe leukocyte adhesion deficiency-I (LAD-I), a life-threatening ultra-rare genetic disorder. While the regulatory milestone is a significant achievement for the biotech firm, the market reacted negatively, with the stock price dropping following the announcement. Analysts suggest the decline may be attributed to a "sell the news" dynamic, as the approval was largely anticipated by investors. Additionally, concerns regarding the commercial scalability and long-term profitability of a treatment for such a rare condition may be weighing on investor sentiment. This development highlights the volatility often seen in the biotech sector following major regulatory decisions.